Loss of Trefoil Factor 1 Accelerates the Immune Response to Colorectal Cancer
Anticancer Research · 2024
DOI: 10.21873/anticanres.17200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Takanori Jinno und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Trefoil Factor-1, Tumor Microenvironment, Mice, Knockout.
Abstract (Originalsprache)
BACKGROUND/AIM: Recent studies suggest that PD-L1 expression in immune cells, rather than tumor cells, plays a key role in tumor immunity. Trefoil factor family 1 (TFF1) is a secreted protein expressed mainly by the gastrointestinal epithelium and is related to the development of malignant disease. This study investigated the effects of TFF1 on tumor immunity in a xenograft mouse model of colorectal cancer (CRC). MATERIALS AND METHODS: MC38 cells were implanted in wild-type (WT) and TFF1KO mice, and the tumor micro-environment was investigated using immunohistochemistry. The circulating immune cells were analyzed using flow cytometry. RESULTS: Tumor growth was suppressed in TFF1KO mice. In the tumor microenvironment, CD8- and CD4-positive T cells and CD11c-positive dendritic cells (DCs) were frequently found in TFF1KO mice. When an immune checkpoint inhibitor was administered to these mice, almost half of the tumors in TFF1KO mice showed a complete response. The number of circulating PD-L1/DCs was markedly associated with tumor volume, with TFF1 deletion accelerating this effect and its injection decreasing it. These findings indicate that loss of TFF1 activates tumor immunity via frequent T-cell priming by DCs, and eventually suppresses tumor growth in CRC. In addition, the number of circulating PD-L1/DCs was identified as a predictive marker of checkpoint-inhibiting therapy efficacy. CONCLUSION: Loss of TFF1 resulted in accelerated immune response to colorectal cancer. Further studies are needed to investigate the precise mechanisms of TFF1 in immunotolerance and develop a novel TFF1-inhibiting immunotherapeutic strategy for CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan jumpei@med.nagoya-u.ac.jp.
Zitieren
APA
Jinno, T., Yamaguchi, J., Ogura, A., Kokuryo, T., Yokoyama, Y., Sunagawa, M., Baba, T., Murata, Y., & Ebata, T. (2024). Loss of Trefoil Factor 1 Accelerates the Immune Response to Colorectal Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.17200
Vancouver
Jinno T, Yamaguchi J, Ogura A, Kokuryo T, Yokoyama Y, Sunagawa M, et al. Loss of Trefoil Factor 1 Accelerates the Immune Response to Colorectal Cancer. Anticancer Research. 2024. doi:10.21873/anticanres.17200
BibTeX
@article{Jinno2024,
author = {Jinno, Takanori and Yamaguchi, Junpei and Ogura, Atsushi and Kokuryo, Toshio and Yokoyama, Yukihiro and Sunagawa, Masaki and Baba, Taisuke and Murata, Yuki and Ebata, Tomoki},
title = {Loss of Trefoil Factor 1 Accelerates the Immune Response to Colorectal Cancer},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17200}
}
EUVIMED